148 related articles for article (PubMed ID: 26030457)
1. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
3. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.
Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M
J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083
[TBL] [Abstract][Full Text] [Related]
5. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
6. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
8. Identification of allosteric inhibitors of p21-activated kinase.
Viaud J; Peterson JR
Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
Lee W; Crawford JJ; Aliagas I; Murray LJ; Tay S; Wang W; Heise CE; Hoeflich KP; La H; Mathieu S; Mintzer R; Ramaswamy S; Rouge L; Rudolph J
Bioorg Med Chem Lett; 2016 Aug; 26(15):3518-24. PubMed ID: 27346791
[TBL] [Abstract][Full Text] [Related]
10. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
Guo C; McAlpine I; Zhang J; Knighton DD; Kephart S; Johnson MC; Li H; Bouzida D; Yang A; Dong L; Marakovits J; Tikhe J; Richardson P; Guo LC; Kania R; Edwards MP; Kraynov E; Christensen J; Piraino J; Lee J; Dagostino E; Del-Carmen C; Deng YL; Smeal T; Murray BW
J Med Chem; 2012 May; 55(10):4728-39. PubMed ID: 22554206
[TBL] [Abstract][Full Text] [Related]
12. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors.
Staben ST; Feng JA; Lyle K; Belvin M; Boggs J; Burch JD; Chua CC; Cui H; DiPasquale AG; Friedman LS; Heise C; Koeppen H; Kotey A; Mintzer R; Oh A; Roberts DA; Rouge L; Rudolph J; Tam C; Wang W; Xiao Y; Young A; Zhang Y; Hoeflich KP
J Med Chem; 2014 Feb; 57(3):1033-45. PubMed ID: 24432870
[TBL] [Abstract][Full Text] [Related]
13. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
Han D; Wang H; Cui W; Zhang B; Chen BZ
Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
[No Abstract] [Full Text] [Related]
14. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
[TBL] [Abstract][Full Text] [Related]
15. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
16. Computational insight into p21-activated kinase 4 inhibition: a combined ligand- and structure-based approach.
Li RJ; Wang J; Xu Z; Huang WX; Li J; Jin SF; Zhao DM; Cheng MS
ChemMedChem; 2014 May; 9(5):1012-22. PubMed ID: 24643945
[TBL] [Abstract][Full Text] [Related]
17. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
19. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
20. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
